Equities analysts forecast that Illumina, Inc. (NASDAQ:ILMN) will post earnings of $1.58 per share for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Illumina’s earnings. The highest EPS estimate is $1.64 and the lowest is $1.55. Illumina reported earnings of $1.32 per share during the same quarter last year, which would suggest a positive year over year growth rate of 19.7%. The firm is expected to issue its next earnings report on Tuesday, February 4th.
On average, analysts expect that Illumina will report full-year earnings of $6.45 per share for the current financial year, with EPS estimates ranging from $6.42 to $6.51. For the next fiscal year, analysts forecast that the business will report earnings of $7.08 per share, with EPS estimates ranging from $6.81 to $7.25. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Illumina.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 24th. The life sciences company reported $1.93 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.53. Illumina had a net margin of 28.14% and a return on equity of 22.05%. The firm had revenue of $907.00 million for the quarter, compared to analyst estimates of $872.65 million. During the same quarter in the previous year, the business posted $1.52 EPS. The firm’s revenue was up 6.3% compared to the same quarter last year.
ILMN has been the topic of a number of recent analyst reports. ValuEngine lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Piper Jaffray Companies cut their target price on shares of Illumina from $348.00 to $341.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Argus upped their target price on shares of Illumina from $300.00 to $340.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Wolfe Research set a $380.00 target price on shares of Illumina and gave the company a “buy” rating in a research note on Friday, October 25th. Finally, Cowen set a $320.00 target price on shares of Illumina and gave the company a “buy” rating in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $333.50.
ILMN stock traded down $1.09 during trading on Monday, reaching $319.67. The stock had a trading volume of 775,314 shares, compared to its average volume of 1,020,383. Illumina has a 1-year low of $263.30 and a 1-year high of $380.76. The company has a current ratio of 6.82, a quick ratio of 6.15 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $47.15 billion, a P/E ratio of 55.89, a PEG ratio of 2.37 and a beta of 1.06. The firm has a fifty day moving average price of $306.65 and a 200 day moving average price of $310.05.
In other news, SVP Charles Dadswell sold 1,220 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $279.88, for a total value of $341,453.60. Following the sale, the senior vice president now owns 5,386 shares in the company, valued at approximately $1,507,433.68. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Phillip G. Febbo sold 155 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $300.00, for a total transaction of $46,500.00. Following the completion of the sale, the senior vice president now owns 1,506 shares in the company, valued at approximately $451,800. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,193 shares of company stock worth $4,884,874. Company insiders own 0.38% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cim Investment Mangement Inc. raised its stake in Illumina by 3.9% during the second quarter. Cim Investment Mangement Inc. now owns 2,383 shares of the life sciences company’s stock worth $877,000 after acquiring an additional 89 shares during the period. Kornitzer Capital Management Inc. KS raised its stake in Illumina by 20.4% during the third quarter. Kornitzer Capital Management Inc. KS now owns 104,845 shares of the life sciences company’s stock worth $31,896,000 after acquiring an additional 17,796 shares during the period. Arjuna Capital acquired a new stake in Illumina during the second quarter worth about $269,000. Sterling Investment Advisors Ltd. raised its stake in Illumina by 14.6% during the third quarter. Sterling Investment Advisors Ltd. now owns 2,165 shares of the life sciences company’s stock worth $659,000 after acquiring an additional 275 shares during the period. Finally, Keudell Morrison Wealth Management acquired a new stake in Illumina during the second quarter worth about $1,483,000. Hedge funds and other institutional investors own 91.77% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: How Important is Technical Analysis of Stocks
Get a free copy of the Zacks research report on Illumina (ILMN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.